GAITHERSBURG, Md.--(BUSINESS WIRE)--At today’s 98th Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, GenVec, Inc. (Nasdaq:GNVC) presented preclinical data illustrating the activity of GenVec’s lead product candidate, TNFerade™, when used in combination with gemcitabine in preclinical models of pancreatic cancer.
